CAREER
My Journey
Diaceutics PTE
Singapore
Kantar Health
Singapore
IQVIA Asia-Pacific
Singapore
AstraZeneca Pharmaceutical Corporation
Gaithersburg, MD, US
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT, US
Millennium Pharmaceutical Company
Cambridge, MA, US
Sanofi
Indianapolis, Indiana
Aventis Pharmaceutical Company
Bridgewater, NJ, US
Eli Lilly Pharmaceutical Company
Indianapolis, IN, US
Diaceutics PTE
Singapore
Vice President, Asia Pacific, Middle East, and Africa – Dec 2020 – Present
- Propelling APAC business revenue 150%+ revenue increase with APAC contributing 25% to global revenue, through strategic planning and execution. Overcoming challenges related to significant company downsizing and the delivery and execution teams being based in the United Kingdom.
- Scaling operations to power growth, securing approval to add 4 FTEs based in the APAC region.
- Navigating the Field-Based team through its change in leadership, boosting performance and customer satisfaction and empowering the team to overachieve its targets and expand business.
- Increasing profitability by eliminating $400K in operational costs.
Kantar Health
Singapore
Senior Client Partner, Real World Evidence (RWE) │ Oncology and Rare Diseases – Nov 2019 – Nov 2020
Entrusted to develop, launch, lead, and grow the real-world evidence division focusing upon registries, databases and observational studies in the APAC region as part of Kantars new global initiative. Successfully led sustainable P&L and EBITDA growth, surpassing the challenge to attain $500K in new RWE sales within the initial year. Managed the portfolio of Oncology RWE assets, including the design and analysis of observational and interventional studies in the APAC region. Planned and executed strategic initiatives driving business across a suite of services, including, real world insights, market access, health outcomes, pricing, reimbursement, and medical services.
- Penetrated new markets and verticals, paving the way into new portfolios and a new business model offering customized, innovative offerings merging real world, qualitative, and quantitative insights. Connected with existing clients to identify opportunities to bridge gaps in offerings through registries, databases, and observational studies.
- Successfully closed $1.6M in RWE revenue within the first year, exceeding the target at 320%. Expanded brand awareness in RWE products, capitalizing on a market shift from a volume-based to value-based approach.
- Identified and seized the opportunity to monetize hospital databases, generating $600K in annual revenue.
- Triggered rapid profitability and increased company visibility in the region by pioneering a revenue stream for publishing abstracts of collaboration projects with pharmaceutical and biotechnology clients. Generated visibility at ISPOR through 12 abstracts and a virtual poster at ESMO ASIA 2020.
IQVIA Asia-Pacific
Singapore
Principal, Strategy-Life Sciences │ Head of APAC Registry and Observational Studies, Real World Insights Division – Sep 2017 – Nov 2019
Recruited to drive the overall RWE expansion strategy for the APAC region and to swiftly turn around the APAC registry revenue (2017) in support of the Asia Pacific Hepatocellular Carcinoma (AHCC) Trials group registry offerings.
- Transformed market performance, catapulting revenue 950% over prior year, and producing $2.8M in total contract value. Traveled internationally to strengthen recruitment. Increased visibility by proposing and executing submission of interim results to ASCO and regional congresses via abstracts, publications, and posters.
- Commercialized and launched syndicated registry and observational studies network in 14 countries for $2.8M total contract value.
- Facilitated optimization of pricing, market access, and reimbursement by providing market, competitor, and customer analyses insights and recommendations to global stakeholders.
- Enhanced solutions portfolio through innovation, designing and delivering new analytic and visual analytic solutions powered by AI and machine learning, such as Oncowave Dashboard (OWD), and oncology data visualization platform.
AstraZeneca Pharmaceutical Corporation
Gaithersburg, MD, US
Senior Medical Science Liaison, Thoracic Cancer-Immuno-Oncology │ Field-Based Medical Affairs – Oncology Division – Sep 2015 – Sep 2017
Developed strategic plans to grow business through collaborative scientific engagements with leading oncologists in southeast US, Puerto Rico, and LATAM. Assessed community practices’ clinical research capabilities and advised on sponsored clinical trial participation. Advanced research initiatives by supporting clinical oncologists via investigator initiated and company-sponsored research programs. Guided oncology research leaders in publication planning and advisory board and consultant forum participation. Partnered with commercial teams, providing medical input and product scientific and technical support.
- Instrumental in leading and supporting the rest of world launch of TAGRISSO® (osimertinib) in LATAM and APAC regions.
- Advanced internal expertise on a Global scale, advised affiliates on pre-launch strategic initiatives, shared learnings from U.S. post-launch challenges, and discussed skills required for gathering key insights by field-based personnel. Facilitated LATAM oncology master class in Colombia. Represented the U.S. medical affairs division as a presenter at global congress events.
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT, US
Associate Director, Field Based Medicine Field Based Medical Affairs – Oncology – Mar 2010 – Sep 2015
- Afatinib Compound Lead, supported the Squamous Cell Carcinoma of the Head and Neck (SCCHN) program. Developed and facilitated Afatinib training workshops for the MSL team (e.g. medical information letter database, development of sales training materials and product slide decks). Developed and maintained SCCHN scientific objectives, utilized as a guidance document for the MSL team. MSL lead and cross-functional team member (clinical operations, legal, etc.) for two ongoing phase III global SCCHN company-sponsored trials.
- Multiple Myeloma (MM) training lead for the MSL team. Developed and delivered scientific training presentations/modules (slide decks, discussion guides) for MSL continuing education and new employee training initiatives. Created annual scientific training objectives and implementation plans.
- Radiation Therapy Oncology Group (RTOG) lead, supported BI oncology scientific objectives, effectively captured and reported clinical and competitive intelligence data to global oncology teams.
Millennium Pharmaceutical Company
Cambridge, MA, US
Senior Medical Science Liaison Field Based Medical Affairs – Oncology
- Scientific and Subject Matter Expert for commercial and cross-functional teams to develop and present scientific data to global oncology thought leaders at consultant meetings, advisory boards and speaker training symposia. Regional trainer for the ortho-biotech sales training collaboration.
- Developed, maintained and leveraged strategic relationships with professional societies. Served as Cooperative Group Lead and ASCO, ASH and ASBMT Corporate Lead.
Sanofi
Indianapolis, Indiana
Manager, Professional Oncology Education (POEM) – Aug 2004 – Mar 2005
Aventis Pharmaceutical Company
Bridgewater, NJ, US
Manager, Professional Medical Education Field Based Medical Affairs – Oncology
- Created, implemented and delivered innovative oncology education strategies to Healthcare Providers (HCP’s) to assist in treatment practices.
- Assessed oncology medical education needs and served as a scientific resource in key therapeutic areas (Prostate, Ovarian, Breast, Gastric, Head & Neck and Lung Cancers). Assisted in the development of educational programs with Continuing Medical Education (CME) providers and educational consultants.
Eli Lilly Pharmaceutical Company
Indianapolis, IN, US
Executive Oncology Business Development Specialist (2001)
Sr. Clinical Project Manager (2000)
- Managed $2M Thoracic (Gemzar/Alimta) budget, and $1M promotional materials budget.
- Attained 116% of quota for territory as Oncology Specialist, resulting in a 16% increase in quota.
- Co-chaired cross-functional thoracic tumor strategy meetings between marketing and medical teams. Moderated advisory boards and consultant meetings.